Mark S. Cohen serves as Executive at Celsus Therapeutics Plc., where they oversee executive responsibilities. Since joining the company, Mark S. Cohen has executed 3 insider transactions totaling $200.6K, demonstrating a bullish approach to their equity position. Their most recent transaction on Sep 18, 2015 involved purchasing 1,055,600 shares valued at $200.6K.
Mark S. Cohen currently holds 1,055,600 shares of Celsus Therapeutics Plc. (CLTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Mark S. Cohen has been a net buyer of CLTX stock. They have purchased $200.6K and sold $0 worth of shares.
Mark S. Cohen's most recent insider trade was on Sep 18, 2015, when they purchased 1,055,600 shares at $0.19 per share.
Get notified when new Form 4 filings are submitted
| $0.02 |
| Discretionary |
| Jan 8, 2015 | CLTX | $1.0K | Exercise | 50,700 | $0.02 | Discretionary |